PROQR THERAPEUTICS NV (PRQR) Stock News
NASDAQ:PRQR - Nasdaq - NL0010872495 - Common Stock - Currency: USD
PRQR Latest News, Press Relases and Analysis
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
ProQR Announces First Quarter 2025 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810...
ProQR Announces First Quarter 2025 Operating and Financial Results
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ProQR Therapeutics (NASDAQ:PRQR) just reported results for the second quarter o...
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T
ProQR Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $5 price target ProQR represents a “true” biotech investment given its early-stage, emerging technology with “a plethora of potential applications,” ovel first in class targets and a wide array of strategic optionality for the company, but over the last few years investors have increasingly focused on derisked targets and indications, which is why the stock is trading at cash despite what the firm calls “s
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
ProQR Announces Year End 2024 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810...
ProQR Announces Year End 2024 Operating and Financial Results
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
ProQR Announces Third Quarter 2024 Operating and Financial Results
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to...
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to...
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to...
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
PRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
ProQR Announces Second Quarter 2024 Operating and Financial Results
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Announces First Quarter 2024 Operating and Financial Results
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to...
ProQR Announces First Quarter 2024 Operating and Financial Results